Literature DB >> 29660300

The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood.

Tali Czarnowicki1, Helen He2, Alexandra Leonard2, Kunal Malik3, Shai Magidi4, Stephanie Rangel5, Krishna Patel5, Kara Ramsey5, Morgan Murphrey5, Teresa Song2, Yeriel Estrada2, Hue-Chi Wen2, James G Krueger6, Emma Guttman-Yassky1, Amy S Paller7.   

Abstract

The ichthyoses are rare skin disorders with immune and barrier aberrations. Identifying blood phenotypes may advance targeted therapeutics. We aimed to compare frequencies of skin homing/cutaneous lymphocyte antigen (+) versus systemic/cutaneous lymphocyte antigen (-) "polar" CD4+/CD8+ and activated T-cell subsets in ichthyosis versus atopic dermatitis, psoriasis, and control blood, with appropriate clinical correlations. Flow cytometry was used to measure IFN-γ, IL-13, IL-9, IL-17, and IL-22 cytokines in CD4+/CD8+ T cells, with inducible co-stimulator molecule and HLA-DR defining mid- and long-term T-cell activation, respectively. We compared peripheral blood from 47 patients with ichthyosis (congenital ichthyosiform erythroderma, lamellar ichthyosis, epidermolytic ichthyosis, and Netherton syndrome) with 43 patients with atopic dermatitis and 24 patients with psoriasis and 59 age-matched controls. Clinical measures included the ichthyosis severity score, with subsets for erythema and scaling, transepidermal water loss, and pruritus. All ichthyoses had excessive inducible co-stimulator molecule activation (P < 0.001), particularly epidermolytic ichthyosis. Significantly elevated IL-17- (P < 0.05) and IL-22-producing (P < 0.01) T cells characterized ichthyoses, mainly Netherton syndrome and congenital ichthyosiform erythroderma (P < 0.05). Increased T helper 2/cytotoxic T cell 2/T helper 9 (P < 0.05) and similar IFN-γ frequencies (P > 0.1) versus controls were also noted. IL-17/IL-22-producing cells clustered with clinical measures, whereas IFN-γ clustered with age. Our data show peripheral blood IL-17/IL-22 activation across the ichthyoses, correlating with clinical measures. Targeted therapies should dissect the relative contribution of polar cytokines to disease pathogenesis.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29660300     DOI: 10.1016/j.jid.2018.03.1523

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

Review 1.  Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses.

Authors:  Amy S Paller
Journal:  J Invest Dermatol       Date:  2019-01-19       Impact factor: 8.551

2.  Secukinumab Therapy for Netherton Syndrome.

Authors:  Isabelle Luchsinger; Nicole Knöpfel; Martin Theiler; Mathilde Bonnet des Claustres; Claire Barbieux; Agnes Schwieger-Briel; Corinne Brunner; Davide Donghi; Michael Buettcher; Barbara Meier-Schiesser; Alain Hovnanian; Lisa Weibel
Journal:  JAMA Dermatol       Date:  2020-08-01       Impact factor: 10.282

3.  Secukinumab responses vary across the spectrum of congenital ichthyosis in adults.

Authors:  Rachel Lefferdink; Stephanie M Rangel; Emma Guttman-Yassky; Amy S Paller; Margot Chima; Erin Ibler; Ana B Pavel; HeeJin Kim; Benedict Wu; Hajar Abu-Zayed; Jianni Wu; Kathryn Jackson; Giselle Singer; Keith A Choate
Journal:  Arch Dermatol Res       Date:  2022-02-26       Impact factor: 3.017

Review 4.  Treatments for Non-Syndromic Inherited Ichthyosis, Including Emergent Pathogenesis-Related Therapy.

Authors:  Divina Justina Hasbani; Lamiaa Hamie; Edward Eid; Christel Tamer; Ossama Abbas; Mazen Kurban
Journal:  Am J Clin Dermatol       Date:  2022-08-12       Impact factor: 6.233

Review 5.  New developments in the molecular treatment of ichthyosis: review of the literature.

Authors:  M D W Joosten; J M K Clabbers; N Jonca; J Mazereeuw-Hautier; A H Gostyński
Journal:  Orphanet J Rare Dis       Date:  2022-07-15       Impact factor: 4.303

Review 6.  Juvenile idiopathic arthritis in Harlequin ichthyosis, a rare combination or the clinical spectrum of the disease? Report of a child treated with etanercept and review of the literature.

Authors:  Francesco Baldo; Michela Brena; Simone Carbogno; Francesca Minoia; Stefano Lanni; Sophie Guez; Antonella Petaccia; Carlo Agostoni; Rolando Cimaz; Giovanni Filocamo
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-03       Impact factor: 3.054

Review 7.  Current Strategies for the Gene Therapy of Autosomal Recessive Congenital Ichthyosis and Other Types of Inherited Ichthyosis.

Authors:  Daria S Chulpanova; Alisa A Shaimardanova; Aleksei S Ponomarev; Somaia Elsheikh; Albert A Rizvanov; Valeriya V Solovyeva
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 5.923

Review 8.  Cytokine-Mediated Crosstalk Between Keratinocytes and T Cells in Atopic Dermatitis.

Authors:  Mélanie Humeau; Katia Boniface; Charles Bodet
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 9.  Proposal for a 6-step approach for differential diagnosis of neonatal erythroderma.

Authors:  E Cuperus; A Bygum; L Boeckmann; C Bodemer; M C Bolling; M Caproni; A Diociaiuti; S Emmert; J Fischer; A Gostynski; S Guez; M E van Gijn; K Hannulla-Jouppi; C Has; A Hernández-Martín; A E Martinez; J Mazereeuw-Hautier; M Medvecz; I Neri; V Sigurdsson; K Suessmuth; H Traupe; V Oji; S G M A Pasmans
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-15       Impact factor: 9.228

10.  Patients with congenital ichthyosis and TGM1 mutations overexpress other ARCI genes in the skin: Part of a barrier repair response?

Authors:  Hanqian Zhang; Maja Ericsson; Simone Weström; Anders Vahlquist; Marie Virtanen; Hans Törmä
Journal:  Exp Dermatol       Date:  2018-12-21       Impact factor: 3.960

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.